• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Seer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/13/25 4:12:26 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    8-K
    false000172644500017264452025-05-132025-05-13

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):

    May 13, 2025

     

     

    Seer, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

     

    001-39747

     

    82-1153150

    (State or other jurisdiction of

     

    (Commission

     

    (I.R.S. Employer

    incorporation)

     

    File Number)

     

    Identification No.)

    3800 Bridge Parkway, Suite 102

    Redwood City, California 94065

    (Address of principal executive offices, including zip code)

    650-453-0000

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last reports)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

     

    Title of each class

    Trading Symbol

    Name of each exchange on which registered

    Class A Common Stock, par value $0.00001 per share

    SEER

    The NASDAQ Stock Market LLC

    (The NASDAQ Global Select Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 2.02

    Results of Operations and Financial Condition.

    On May 13, 2025, Seer, Inc. issued a press release (the “Press Release”) announcing results for the quarter ended March 31, 2025. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

    The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

     

     


     

    Item 9.01

    Financial Statements and Exhibits.

     

     

    Exhibit No.

     

    Description

    99.1

     

    Press Release dated May 13, 2025.

    104

     

    Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    SEER, INC.

     

     

     

     

     

    Date: May 13, 2025

     

    By:

     

    /s/ David Horn

     

     

     

     

    David Horn

     

     

     

     

    President and Chief Financial Officer

     

     


    Get the next $SEER alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CFO Horn David R. sold $13,955 worth of shares (6,827 units at $2.04), decreasing direct ownership by 2% to 436,802 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    8/21/25 4:19:37 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO AND CHAIR Farokhzad Omid sold $69,483 worth of shares (33,992 units at $2.04), decreasing direct ownership by 3% to 1,272,068 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    8/21/25 4:18:17 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Roelofs Nicolas H Phd was granted 17,083 shares, increasing direct ownership by 29% to 74,996 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    7/9/25 4:14:44 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Seer Inc.

    SCHEDULE 13G/A - Seer, Inc. (0001726445) (Subject)

    8/13/25 4:24:17 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Seer Inc.

    10-Q - Seer, Inc. (0001726445) (Filer)

    8/6/25 4:24:21 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Seer, Inc. (0001726445) (Filer)

    8/6/25 4:16:51 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

    Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Achieved revenue of $4.1 million for the second quarter of 2025Launched new high-throughput Proteograph ONE assay and SP200 automation instrument, enabling previously unattainable scale and efficiencyAnnounced a collaboration with Korea University to launc

    8/6/25 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

    REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Seer's management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the conference. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbi

    7/31/25 4:05:54 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

    REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed,

    7/22/25 4:05:05 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by JP Morgan with a new price target

    JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously

    8/11/22 6:17:02 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

    Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Achieved revenue of $4.1 million for the second quarter of 2025Launched new high-throughput Proteograph ONE assay and SP200 automation instrument, enabling previously unattainable scale and efficiencyAnnounced a collaboration with Korea University to launc

    8/6/25 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

    REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed,

    7/22/25 4:05:05 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

    REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life SciencesAccelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviewsEnded the quarter with approximately $285 million of cash, cash equivalents and investments "We are proud of our

    5/13/25 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

    REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented

    3/16/22 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Appoints Meeta Gulyani to its Board of Directors

    REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada. "Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Me

    11/29/21 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials